Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus

Oncogene

Volumn 34, Issue 2, 2015, Pages 246-256

  Batlle Lopez A ^a,b   Cortiguera, M G ^a,b   Rosa Garrido, M ^a,d   Blanco, R ^a   Del Cerro, E ^b   Torrano, V ^a,e   Wagner, S D ^c   Delgado, M D ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CIC BIOGUNE   (Spain)

Author keywords

BCL6; CTCF; epigenetics; germinal centre; lymphoma

Indexed keywords

BCL6 PROTEIN, HUMAN; CCCTC-BINDING FACTOR; DNA BINDING PROTEIN; HISTONE; REPRESSOR PROTEIN;

B LYMPHOCYTE; BINDING SITE; CPG ISLAND; EXON; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; K562 CELL LINE; LYMPHOMA; METABOLISM; PATHOLOGY; PLASMA CELL; TUMOR CELL LINE;

B-LYMPHOCYTES; BINDING SITES; CELL LINE, TUMOR; CPG ISLANDS; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; EXONS; HISTONES; HUMANS; K562 CELLS; LYMPHOMA; PLASMA CELLS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84890517461     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.535     Document Type: Article

References (59)

1. Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R et al. The BCL-6 protooncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16: 161-170.
2. Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012; 247: 172-183.
3. Fearon DT, Manders PM, Wagner SD. Bcl-6 uncouples B lymphocyte proliferation from differentiation. Adv Exp Med Biol 2002; 512: 21-28.
4. Reljic R, Wagner SD, Peakman LJ, Fearon DT. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med 2000; 192: 1841-1848.
5. Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 2010; 105: 193-210.
6. Wagner SD, Ahearne M, Ko Ferrigno P. The role of BCL6 in lymphomas and routes to therapy. Br J Haematol 2011; 152: 3-12.
7. Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7: 445-455.
8. Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914-2923.
9. Wang X, Li Z, Naganuma A, Ye BH. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2002; 99: 15018-15023.
10. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol 2005; 6: 303-313.
11. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12: 280-292.
12. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012; 481: 90-93.
13. Niu H, Ye BH, Dalla-Favera Rk. Antigen receptor signaling induces MAP kinasemediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998; 12: 1953-1961.
14. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606-613.
15. Papadopoulou V, Postigo A, Sanchez-Tillo E, Porter AC, Wagner SD. ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. Biochem J 2010; 427: 541-550.
16. Batlle A, Papadopoulou V, Gomes AR, Willimott S, Melo JV, Naresh K et al. CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol Immunol 2009; 46: 1727-1735.
17. Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 2010; 207: 1939-1950.
18. Ohlsson R, Lobanenkov V, Klenova E. Does CTCF mediate between nuclear organization and gene expression? Bioessays 2010; 32: 37-50.
19. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009; 137: 1194-1211.
20. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007; 128: 1231-1245.
21. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008; 133: 1106-1117.
22. Wang H, Maurano MT, Qu H, Varley KE, Gertz J, Pauli F et al. Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res 2012; 22: 1680-1688.
23. Lee BK, Bhinge AA, Battenhouse A, McDaniell RM, Liu Z, Song L et al. Cell-type specific and combinatorial usage of diverse transcription factors revealed by genome-wide binding studies in multiple human cells. Genome Res 2012; 22: 9-24.
24. Herold M, Bartkuhn M, Renkawitz R. CTCF: insights into insulator function during development. Development (Cambridge, England) 2012; 139: 1045-1057.
25. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
26. Cuddapah S, Jothi R, Schones DE, Roh TY, Cui K, Zhao K. Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. Genome Res 2009; 19: 24-32.
27. Parelho V, Hadjur S, Spivakov M, Leleu M, Sauer S, Gregson HC et al. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 2008; 132: 422-433.
28. Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, Schirghuber E et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 2008; 451: 796-801.
29. Yusufzai TM, Tagami H, Nakatani Y, Felsenfeld G. CTCF tethers an insulator to subnuclear sites, suggesting shared insulator mechanisms across species. Mol Cell 2004; 13: 291-298.
30. van de Nobelen S, Rosa-Garrido M, Leers J, Heath H, Soochit W, Joosen L et al. CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics & chromatin 2010; 3: 19.
31. Filippova GN. Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol 2008; 80: 337-360.
32. Klenova EM, Nicolas RH, Paterson HF, Carne AF, Heath CM, Goodwin GH et al. CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 1993; 13: 7612-7624.
33. De La Rosa-Velazquez IA, Rincon-Arano H, Benitez-Bribiesca L, Recillas-Targa F. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF. Cancer Res 2007; 67: 2577-2585.
34. Soto-Reyes E, Recillas-Targa F. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 2010; 29: 2217-2227.
35. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009; 34: 271-284.
36. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res 2005; 33: 6850-6860.
37. Bernardin F, Collyn-d'Hooghe M, Quief S, Bastard C, Leprince D, Kerckaert JP. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation. Oncogene 1997; 14: 849-855.
38. Bao L, Zhou M, Cui Y. CTCFBSDB: a CTCF-binding site database for characterization of vertebrate genomic insulators. Nucleic Acids Res 2008; 36: D83-D87.
39. Ziebarth JD, Bhattacharya A, Cui Y. CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization. Nucleic Acids Res 2013; 41: D188-D194.
40. Kikuchi M, Miki T, Kumagai T, Fukuda T, Kamiyama R, Miyasaka N et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene 2000; 19: 4941-4945.
41. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
42. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
43. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86: 45-53.
44. Bottardi S, Aumont A, Grosveld F, Milot E. Developmental stage-specific epigenetic control of human beta-globin gene expression is potentiated in hematopoietic progenitor cells prior to their transcriptional activation. Blood 2003; 102: 3989-3997.
45. Szutorisz H, Canzonetta C, Georgiou A, Chow CM, Tora L, Dillon N. Formation of an active tissue-specific chromatin domain initiated by epigenetic marking at the embryonic stem cell stage. Mol Cell Biol 2005; 25: 1804-1820.
46. Yoon B, Herman H, Hu B, Park YJ, Lindroth A, Bell A et al. Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol 2005; 25: 11184-11190.
47. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D et al. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007; 35: 7372-7388.
48. Fitzpatrick GV, Pugacheva EM, Shin JY, Abdullaev Z, Yang Y, Khatod K et al. Allelespecific binding of CTCF to the multipartite imprinting control region KvDMR1. Mol Cell Biol 2007; 27: 2636-2647.
49. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-7762.
50. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763-7774.
51. Ramachandrareddy H, Bouska A, Shen Y, Ji M, Rizzino A, Chan WC et al. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells. Proc Natl Acad Sci USA 2010; 107: 11930-11935.
52. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-466.
53. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010; 31: 974-983.
54. Ishihara K, Oshimura M, Nakao M. CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 2006; 23: 733-742.
55. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
56. Torrano V, Chernukhin I, Docquier F, D'Arcy V, Leon J, Klenova E et al. CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. J Biol Chem 2005; 280: 28152-28161.
57. Torrano V, Navascues J, Docquier F, Zhang R, Burke LJ, Chernukhin I et al. Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly-(ADP-ribosyl)ation-dependent mechanism. J Cell Sci 2006; 119: 1746-1759.
58. Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A. A cell cycle role for the epigenetic factor CTCF-L/BORIS. PLoS One 2012; 7: e39371.
59. Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW et al. Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation. Hum Mol Genet 2005; 14: 953-965.